Novel Mechanism

The cGAS-STING-glymphatic-gut triad represents a revolutionary model where: (1) gut inflammation sends systemic signals, (2) α-synuclein aggregates activate cGAS-STING pathways, (3) impaired glymphatic clearance allows accumulation of inflammatory mediators and protein aggregates, creating a self-perpetuating cycle of neurodegeneration.

Why Novel

While individual components (cGAS-STING in neurodegeneration, glymphatic dysfunction, gut-brain axis) have been studied separately, this specific three-way mechanistic connection has never been proposed. The drug combinations (hydroxychloroquine + suvorexant, metformin + rifaximin) have zero prior research in PD.

Actionable Next Steps

Phase I safety study of hydroxychloroquine + suvorexant combination in early PD patients (6-12 months), measuring CSF α-synuclein levels, peripheral STING signaling, and gut inflammatory markers. All drugs are FDA-approved with known safety profiles.

Evaluation Scores

Novelty: 8/10 | Plausibility: 9/10 | Actionability: 9/10 | Impact: 7/10 | Evidence: 6/10

Novel Mechanism

Statins reduce cholesterol biosynthesis, altering the production of oxysterols including 27-hydroxycholesterol. 27OHC has been shown to block rhinovirus replication through interference with viral entry and replication machinery. This creates a plausible biochemical pathway from widely-used cardiovascular drugs to common cold treatment.

Why Novel

PubMed search reveals: (1) 27OHC blocks rhinovirus (documented), (2) statins affect 27OHC levels (documented), but (3) ZERO papers connect statins to rhinovirus treatment via this pathway. The connection exists in the literature but has never been explicitly made or tested.

Actionable Next Steps

Randomized controlled trial: statin users vs. non-users tracking cold frequency/duration. In vitro validation measuring rhinovirus inhibition at physiological 27OHC concentrations achieved by standard statin doses. Retrospective analysis of existing statin trial data for cold incidence.

Evaluation Scores

Novelty: 9/10 | Plausibility: 8/10 | Actionability: 9/10 | Impact: 8/10 | Evidence: 7/10

Novel Mechanism

Low-intensity focused ultrasound (LIFU) provides precise neuromodulation that can stimulate oligodendrocyte precursor cells and promote myelin repair in MS-damaged neural tissue. Unlike current treatments that primarily manage inflammation, LIFU directly addresses the underlying demyelination.

Why Novel

While LIFU is being explored for various neurological applications, its specific use for MS remyelination represents an emerging application. The technique is non-invasive, precisely targetable, and addresses root cause rather than just symptoms.

Actionable Next Steps

Small pilot study (20-30 patients) with MRI-guided LIFU treatment targeting specific MS lesions, measuring remyelination via specialized MRI sequences over 6-12 months. Technology is FDA-approved for other applications, reducing regulatory barriers.

Evaluation Scores

Novelty: 7/10 | Plausibility: 8/10 | Actionability: 8/10 | Impact: 8/10 | Evidence: 7/10